Ancestry-specific predisposing germline variants in cancer

Authors: Ninad Oak, Andrew D. Cherniack, R. Jay Mashl, Jian Carrot-Zhang, Jian Carrot-Zhang, Nyasha Chambwe, Jeffrey S. Damrauer, Theo A. Knijnenburg, A. Gordon Robertson, Christina Yau, Wanding Zhou, Ashton C. Berger, Kuan-lin Huang, R. Jay Mashl, Justin Newberg, Alessandro Romanel, Rosalyn W. Sayaman, Francesca Demichelis, Ina Felau, Garret Frampton, Seunghun Han, Katherine A. Hoadley, Anab Kemal, Peter W. Laird, Alexander J. Lazar, Xiuning Le, Ninad Oak, Hui Shen, Christopher K. Wong, Jean C. Zenklusen, Elad Ziv, Francois Aguet, Li Ding, John A. Demchok, Michael K. A. Mensah, Roy Tarnuzzer, Zhining Wang, Liming Yang, Jessica Alfoldi, Konrad J. Karczewski, Daniel G. MacArthur, Garret M. Frampton, Christopher Benz, Joshua M. Stuart, Andrew D. Cherniack, Rameen Beroukhim, Fred R. Hirsch, Li Ding, Rameen Beroukhim, Zeynep H. Gümüş, Sharon E. Plon, Kuan-lin Huang ⚬

Affiliations: grid.240871.80000 0001 0224 711XDepartment of Oncology, St. Jude Children’s Research Hospital, Memphis, TN 38105 USA; grid.39382.330000 0001 2160 926XDepartment of Molecular and Human Genetics, Baylor College of Medicine, Houston, TX 77030 USA; grid.66859.34The Eli and Edythe L. Broad Institute of Massachusetts Institute of Technology and Harvard University, Cambridge, MA 02142 USA; grid.65499.370000 0001 2106 9910Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215 USA; grid.4367.60000 0001 2355 7002Department of Medicine, Washington University in St. Louis, St. Louis, MO 63108 USA; grid.4367.60000 0001 2355 7002McDonnell Genome Institute, Washington University in St. Louis, St. Louis, MO 63108 USA; grid.59734.3c0000 0001 0670 2351Department of Oncological Sciences, Center for Thoracic Oncology, Tisch Cancer Institute, New York, NY USA; grid.4367.60000 0001 2355 7002Department of Genetics, Washington University in St. Louis, St. Louis, MO 63108 USA; grid.4367.60000 0001 2355 7002Siteman Cancer Center, Washington University in St. Louis, St. Louis, MO 63108, USA; grid.62560.370000 0004 0378 8294Department of Medicine, Brigham and Women’s Hospital and Harvard Medical School, Boston, MA USA; grid.59734.3c0000 0001 0670 2351Department of Genetics and Genomics, Icahn School of Medicine at Mount Sinai, New York, NY 10029 USA; grid.59734.3c0000 0001 0670 2351Icahn Institute for Data Science and Genomic Technology, Icahn School of Medicine at Mount Sinai, New York, NY 10029 USA; grid.39382.330000 0001 2160 926XHuman Genome Sequencing Center, Baylor College of Medicine, Houston, TX 77030 USA; grid.39382.330000 0001 2160 926XDepartment of Pediatrics, Baylor College of Medicine, Houston, TX 77030 USA; grid.59734.3c0000 0001 0670 2351Center for Transformative Disease Modeling, Icahn School of Medicine at Mount Sinai, New York, NY 10029 USA

License: © The Author(s) 2020 CC BY 4.0 Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Article links: DOI: 10.1186/s13073-020-00744-3  |  PubMed: 32471518  |  PMC: PMC7260738

Relevance: Moderate: mentioned 3+ times in text

Full text: PDF (1.1 MB)

Background

Cancer risk differs across ancestries. According to the National Cancer Institute’s Surveillance, Epidemiology, and End Results (SEER) program, the cancer incidence per 100,000 ranges from 449 in race/ethnicity population self-identified as Whites, 453 in Blacks, 298 in Asian/Pacific Islanders, 315 in American Indian/Alaskan Natives, and 336 in Hispanics in the USA between 2011 and 2015 [ref. 1, ref. 2]. While some of these differences may be attributed to non-genetic factors such as access to health care or diet, much can likely be explained by differences in the genomic architecture of these ancestries and differing frequencies of inherited genetic predisposition. Previous studies revealed different carrier rates of pathogenic variants across ancestries, albeit often in a limited panel of genes or selected cancer types [ref. 3–ref. 5].

While multiple large-scale genome-wide association studies have investigated the common risk variants contributing to cancer [ref. 6–ref. 10], fewer studies have interrogated rare pathogenic variants in non-European ancestries [ref. 5, ref. 11–ref. 15]. A 2019 systematic review of cancer sequencing studies found a total of only 764 reported non-European (minority) cases in 27 published studies with reported race/ethnicity [ref. 9]. Consequently, germline genetic testing in non-White patients often results in higher rates of variants of unknown significance (VUSs) [ref. 16]. Ongoing efforts are bridging the knowledge gap of cancer genetic predisposition in under-studied populations [ref. 17–ref. 19]. Meanwhile, systematic cross-ancestry investigations of predisposing variants across cancer types are urgently needed to inform genetic testing for each ancestral group.

Herein, we analyzed germline variant data of 9899 cancer cases across 33 cancer types from the Cancer Genome Atlas Project (TCGA) [ref. 20] to identify ancestry-specific cancer-gene associations where the genes show an excess of pathogenic/likely pathogenic germline variants the TCGA samples. In samples of African ancestry, we identified two associations, BRCA2 in lung squamous cell carcinoma (LUSC) and ovarian serous cystadenocarcinoma (OV). In analyses of individuals with East Asian ancestry, we identified an association for BRIP1 in stomach adenocarcinoma (STAD). Using a rare-variant association analysis, we identified seven additional suggestive cancer gene associations. Evidence of a somatic second hit event (i.e., loss of heterozygosity [LOH] or a biallelic mutation) was found in two thirds of the tumors with germline predisposing variants. Many carriers of ancestry-specific predisposition variants showed altered expression of the affected genes, including allelic-specific expression (ASE), mis-splicing, and reduced tumor suppressor gene expression, further supporting these genetic variants’ contribution to cancer predisposition.

Methods

Study cohort and genetic ancestry assignment

We used the clinical data provided by TCGA PanCanAtlas and restricted analyses to those with pass-QC blood/normal sequencing data. In addition to excluding cases with PanCanAtlas blacklisted germline BAM-files, cases with less than 60% genotype concordance between sequencing variant calls and SNP-genotype data were eliminated, where 10,389 cases were left [ref. 20]. We further overlapped with the cases included in the PanCanAtlas Ancestry Informative Markers (AIM) genetic ancestry assignment, resulting in the final set of 9899 samples. The detailed descriptions of ancestry assignment procedures are available in the marker publication [ref. 21].

Briefly, consensus genetic ancestry for each TCGA case was determined as the majority of ancestry assignments that were independently determined by five methods across four institutions. These methods include those based on SNP-array genotypes used by Broad Institute, University of California San Francisco (UCSF), and Washington University (WashU), as well as those based on whole-exome sequencing data used by University of Trento and ExAC/Broad Institute. The five methods conducted variations of principal component analyses (PCA) on TCGA normal samples to infer genetic ancestry. We further provide the PCA plots showing the alignment of the major PCs in the UCSF and WashU analyses with the AIM-group consensus genetic ancestry in Additional file 1: Fig. S1.

For each sample, the percentage of global ancestry of African, European, East Asian, Native/Latin American, and South Asian (k = 5) was further estimated using ADMIXTURE [ref. 22] version 1.23 based on the common SNP markers (1000 genomes allele frequency (AF) > 1%) in the Broad Institute analysis. Samples with the proportion of the secondary ancestry greater than 20% were considered as admixed samples (Additional file 2: Table S1). Sensitivity analyses revealed increased power by including admix samples in this cohort. Thus, cases with admixed ancestry assignments were grouped to their nearest neighbors (e.g., afr_admix to afr) for downstream analyses.

Pathogenic and likely pathogenic germline variant calls

We downloaded the overall and predisposing germline variant calls previously reported by the PanCanAtlas Germline Analyses Working Group (https://gdc.cancer.gov/about-data/publications/PanCanAtlas-Germline-AWG) [ref. 20]. The detailed description of variant calling and classification procedures are available in the TCGA PanCanAtlas germline publication [ref. 20].

Briefly, germline SNVs were identified using the union of variant calls between Varscan [ref. 23] and GATK [ref. 24]. Germline indels were identified using Varscan, GATK, and Pindel [ref. 25], and we only retained variants called by at least two out of the three callers or high-confidence Pindel-unique calls (at least 30× coverage and 20% variant allele fraction [VAF]). We used the GRCh37-lite reference. We further required the variants to have an allelic depth (AD) ≥ 5 for the alternative allele. We then used bam-readcount to quantify the number of reference and alternative alleles in both normal and tumor samples. We required the variants to have at least 5 counts of the alternative allele and an alternative allele frequency of at least 20%. Of these, we included those rare variants with ≤ 0.05% allele frequency in 1000 Genomes and ExAC (release r0.3.1). We subsequently retained only cancer-relevant pathogenic variants, based on whether they were found in the curated cancer variant databases or a 152 curated cancer predisposing gene list. Finally, we manually reviewed all variants using integrative genomics viewer (IGV) and filtered out variants with poor support sequence reads.

The variants defined by the above pipeline were then classified using an automatic pipeline termed CharGer [ref. 26] (https://github.com/ding-lab/CharGer) that adopts the American College of Medical Genetics and Genomics/Association of Molecular Pathology (ACMG/AMP) variant classification guidelines which are designed for assessment of germline variants in Mendelian disorders [ref. 27]. For the CharGer classification pipeline, we defined 12 pathogenic evidence levels and 4 benign evidence levels using a number of datasets, including ExAC and ClinVar. The pathogenic evidence adds points, whereas benign evidence subtracts points that amount to pathogenicity (pathogenic requires the variant to be described as pathogenic by the reviewed clinical significance in ClinVar (not including variants showing “conflicting interpretations of pathogenicity”) or other cancer predisposition gene databases, likely pathogenic requires CharGer score > 8). To acquire enough CharGer points to be classified as likely pathogenic, the variants typically need to be predicted to result in truncation in cancer predisposition genes where the loss of function (LOF) is a known disease mechanism and harbor variants with a dominant (evidence level PVS1, + 8 points) or a recessive (evidence level PSC1, + 4 points) mode of inheritance. Additionally, evidence level PS1, + 7 points are scored if the variant results in the same peptide sequence change as an established pathogenic variant. All other modules will each add ≤ 2 points.

Principal component analysis (PCA)

Birdseed genotype files were downloaded from Genomic Data Commons (GDC) in the legacy (hg19) archive onto Institute for System Biology-Cancer Genome Cloud (ISB-CGC), converted to individual VCF files, and then merged into a combined VCFs containing 11,459 samples and 522,606 variants. We conducted PCA as implemented by PLINK (v1.9) [ref. 28]. Specifically, we retained 298,004 variants with AF > 0.15 for population structure analysis. The resulting eigenvalues and eigenvectors were then recorded. PC1 and PC2 accounted for 51.6% and 29.2% of the variations across the first 20 PCs, and none of the trailing PCs accounted for more than 3.2%. Thus, we subsequently controlled for PC1 and PC2 in ancestry-specific cancer predisposing gene analysis (Additional file 1: Fig. S1).

Multivariate regression to identify the enrichment of pathogenic variants

For each cancer type within each ancestry, we conducted multivariate logistic regression analyses considering the case status of the cancer type as the dependent variable (using all other cancer cohorts as controls) and the carrier status of each predisposing gene as an independent variable. The model corrected for age at the initial pathologic diagnosis, gender, and the first two principal components (accounted for 80.8% variations across the first 20 PCs). All ancestry cohorts are called using the same variant calling pipeline, thus avoiding the potential danger of comparing this population against other cohorts such as ExAC. We collapsed predisposing (pathogenic and likely pathogenic) germline variants to the gene level. Only ancestry-cancer combinations with at least 20 cases and predisposing genes with at least two individuals with predisposing variants within the cohort are tested. In total, we tested 33 cancers in European Ancestry, 15 cancers in African Ancestry, and 8 cancers in East Asian ancestry that met this criterion. No cohorts of the Native/Latin American and South Asian ancestry have sufficient sample sizes in TCGA for testing. Among these tested cancers, we tested a total of 114 cancer-gene combinations for multivariate regression analysis, of which 101 were within European ancestry, 9 were in African ancestry, and 4 were in East Asian ancestry. P values were calculated using the Wald test and adjusted to FDR using the standard Benjamini-Hochberg procedure.

Burden testing of pathogenic variants

We conducted burden testing of the cohort within each ancestry as defined by the TCGA AIM working group. Specifically, we adopted the Total Frequency Test (TFT) [ref. 29] by collapsing predisposing (pathogenic and likely pathogenic) germline variants to the gene level. For each cancer type with at least 20 cases of the tested ancestry with at least one predisposing variant carrier, we tested the burden of predisposing variants for each gene against all other cancer cohorts as controls. Among the cancers that met the sample size criteria described above, we tested a total of 120 cancer-gene combinations using rare variant burden testing, of which 104 were within European ancestry, 11 were in African ancestry, and 5 were in East Asian ancestry. The resulting P values were adjusted to FDR using the standard Benjamini-Hochberg procedure.

gnomAD analysis

We analyzed the gene-level and variant-level frequency of the identified genetic predisposition using the non-cancer subset of the genome aggregation database (gnomAD-non-cancer) cohort (118,479 WES and 15,708 WGS samples) [ref. 30, ref. 31] (http://gnomad.broadinstitute.org). For the gene-level analysis, we retained rare variants with ancestry-specific minor allele frequency < 0. 5%. We further retained pathogenic and likely pathogenic variants per ACMG/AMP criteria as ascertained by InterVar [ref. 32] and annotated using ANNOVAR [ref. 33]. Allele frequencies were summarized at gene-level within each sub-population in gnomAD using total allele counts and maximum allele numbers within each group.

The lolliplot diagrams in Fig. 2 were constructed and modified using protein paint (https://pecan.stjude.cloud/proteinpaint).

Expression analysis

TCGA level-3 normalized RNA expression data were downloaded from Firehose (2016/1/28 analysis archive). The tumor expression percentile of individual genes in each cancer cohort was calculated using the empirical cumulative distribution function (ecdf), as implemented in R. We annotated germline carriers of predisposition variants with extreme mRNA tumor expression (> 80th or < 20th percentile) of the affected gene. For samples within the same ancestry and same cancer cohort, we then used the two-sample Kolmogorov-Smirnov test to compare the expression percentile distribution between variants of oncogenes and tumor suppressors. The resulting P values were adjusted to false discovery rate (FDR) using the standard Benjamini-Hochberg procedure.

For the ancestry-specific variants, we recorded the RNA VAF of the mutant allele in the RNA-Seq bam files. For splice site variants, we assessed the mis-splicing of the transcript and variants using IGV.

Power and downsampling analysis

Post hoc power analyses were performed using R-package SKAT [ref. 34] and the power_logistic function to calculate the number of samples for rare variant association with causal percentage = 80%, minor allele frequency < 0.1%, and using odds ratio (OR) > 1 through OR < 10. Each calculation was performed using 100 simulations over a target 5 kb region.

Additionally, we performed a downsampling analysis for each tumor type by random sampling of subsets of samples with incremental sizes from zero to the total number of samples in that tumor type. We identified the number of significantly mutated genes as described above within each subset and plotted a smoothed function (loess method) against the subset size. Each calculation was performed at ten iterations (Additional file 1: Fig. S2).

Results

Ancestry demographics of TCGA cohort

We classified the 9899 TCGA cases with pass-QC germline data across 33 cancer types by genotype-defined ancestries defined by the PanCanAtlas Ancestry Informative Markers (AIM) working group (Additional file 1: Fig. S1, the “Methods” section, Table 1). The European ancestry contained 82.68% (n = 8184) of individuals in this cohort. The remainder of the cohort consisted of 9.76% (n = 966) African ancestry, 6.56% (n = 649) East Asian ancestry, 0.48% (n = 48) South Asian ancestry, 0.41% (n = 41) Native/Latin American ancestry, and 0.11% (n = 11) mixed ancestry. The largest ancestry-specific tumor cohorts are breast invasive carcinoma (BRCA) for the European ancestry (n = 811) and African ancestry (n = 180), liver hepatocellular carcinoma (LIHC) for the East Asian ancestry (n = 162), and thyroid carcinoma (THCA) for the Native/Latin American ancestry (n = 11) and the South Asian ancestry (n = 11).

Ancestry-specific cancer predisposing genes

Acknowledging the limited power to assess ancestry-specific associations as shown by the post hoc power analyses (Additional file 1: Fig. S2), we sought to identify cancer predisposing genes within each ancestry. We considered cancer predisposing genes as those statistically enriched for pooled pathogenic and likely pathogenic variants (referred to here as predisposing variants) as previously classified [ref. 20]). For each ancestry-cancer type pair, we conducted multivariate regression analyses correcting for onset age, gender, and the first two principal components.

Along with 36 cancer-gene associations (FDR < 0.05, Wald test) found in the European ancestry, we identified two specific cancer-gene associations in the African ancestry: BRCA2 in ovarian cancer (OV) (OR = 8.5 [95% CI, 1.5–47.4]; FDR = 0.045) and LUSC (OR = 41.4 [95% CI, 6.1–275.6]; FDR = 0.002). We also identified one association in the East Asian ancestry, BRIP1 in STAD (OR = 12.8 [95% CI, 1.8–90.84]; FDR = 0.038) (Fig. 1, Additional file 2: Table S2a). While the association of BRCA2 and LUSC is first described in African-American ancestry here, BRCA2 was previously found to be associated with non-small cell lung cancer (including LUAD and LUSC) and ovarian cancer (OV) in the European ancestry [ref. 35–ref. 37]. The association of BRIP1 predisposition to STAD in the East Asian ancestry was also previously reported for the European ancestry [ref. 38]. These findings (including novel associations) in a large heterogeneous cancer population build on older studies that evaluated individual cancer predisposition genes and cancer risk across ancestries.

The top associated predisposing genes and their carrier frequency vary widely across ancestries (Fig. 1a). For genes with a significant association in the African ancestry, we observed a higher carrier frequency compared to other ancestries. For example, in LUSC, BRCA2 predisposing variants were found in 2 of the 29 African ancestry samples (6.9%), whereas we only found 1 BRCA2 carrier out of the 455 European-ancestry samples (0.44%).

We next investigated whether the cross-ancestry differences in predisposing gene frequencies were also observed in other cohorts. Specifically, we examined the gene-level rates of individuals carrying pathogenic and likely pathogenic variants in the gnomAD non-cancer cohort [ref. 30, ref. 31] (118,479 WES and 15,708 WGS samples, the “Methods” section, Additional file 2: Table S3). BRCA2 showed the highest frequency in the African ancestry (0.072%) than all other defined ancestries, including non-Finnish European (0.048%) and East Asian (0.047%). BRIP1 also showed higher frequency in the East Asian ancestry (0.068%) than all ancestries (≤ 0.045%) except for the non-Finnish European ancestry (0.099%).

To generate hypotheses for future targeted studies, we investigated additional ancestry-implicated genes using total frequency testing (TFT) of predisposing variants, fully acknowledging potential confounders using this method (Additional file 2: Table S2b). We identified 7 suggestive (FDR < 0.05 in the TFT analysis) ancestry-specific cancer-gene associations in the African ancestry, 6 of which have been previously described including SDHB in PCPG [ref. 39], ATM in PRAD [ref. 40, ref. 41], FH in KIRP [ref. 42], VHL in KIRC [ref. 43], PTEN in UCEC [ref. 44], and BRCA2 in OV [ref. 12]. We also re-discovered the BRCA2 in LUSC described above. In the East Asian ancestry, we identified 3 borderline-suggestive associations (FDR = 0.32): RECQL in STAD, BRIP1 in STAD, and POLE in LIHC. In STAD, RECQL and BRIP1 each affected 2 of the 90 East Asian ancestry cases, but none of the 294 European-ancestry cases. In LIHC, two protein-truncating variants were seen in POLE among 162 East Asian ancestry cases compared to none in 179 European-ancestry cases. These suggestive associations remain to be established and are only used to identify potential predisposing variants with supporting somatic evidence.

Ancestry-specific predisposing variants

We next examined ancestry-specific predisposition at the variant level (Fig. 2, Additional file 2: Table S4) for the 3 significant associations from the multivariate logistic regression analyses and the 7 suggestive associations from the TFT analysis. The cancer-gene pairs included 15 predisposing variants within the African ancestry and another 6 within the East Asian ancestry.

None of the above variants discovered in the African ancestry were observed in any other ancestry within that cancer type (Fig. 2). Across the pan-cancer TCGA cohort, all of the BRCA2 frameshift variants found in LUSC and OV were unique to the African ancestry. For other associated genes in the African ancestry, including ATM (PRAD), FH (KIRP), and VHL (KIRC), the predisposing variants differ between the African and European ancestries (Fig. 2b). The African ancestry-specific predisposing variants include splice site variants ATM c.2921+1G>A and FH c.556-2A>T, protein-truncating variants ATM p.T2333fs and FH p.S187*, and missense variants ATM p.R3008C. VHL p.C162F is the only recurrent variant found in two KIRC cases.

In the East Asian ancestry, we assessed predisposing variants in BRIP1 (STAD), POLE (LIHC), and RECQL (STAD) (Fig. 2a and c). These include two BRIP1 variants p.I525fs and p.E1222fs and two protein-truncating variants in POLE and RECQL, respectively. All six predisposing variants were not shared with any other ancestry in the TCGA cohort (Fig. 2c).

We further analyzed the frequency of these variants of the gnomAD non-cancer dataset [ref. 30, ref. 31]. Among the African ancestry-specific predisposing variants, splice-site variant ATM c.2921+1G>A (African ancestry allelic count [AC]/total allele number [AN] = 1/14,878; allelic frequency [AF] = 0.0067%) and BRCA2 p.R3128* (African ancestry AC/AN = 4/23,610; AF = 0.016%) were the only variants present in the African and non-Finnish European ancestries in gnomAD-non-cancer dataset. All other variants were absent within African ancestry and most other ancestries in gnomAD except SDHB p.R46* (Finnish European ancestry AC/AN = 2/25,066; AF = 0.007%) and ATM p.R3008C (East Asian ancestry AC/AN = 1/17,688; AF = 0.005%). Similarly, only two of the six East Asian ancestry-specific predisposing variants, BRIP1 p.E1222Gfs (East Asian ancestry AC/AN = 11/19,232; AF = 0.05%) and POLE p.Tyr1078fs (East Asian ancestry AC/AN = 1/17,692; AF = 0.005%), were present exclusively in the East Asian ancestry of gnomAD-non-cancer dataset. Of note, 7 of the 15 predisposing variants, including BRCA2 variants in OV (p.Y1710fs, p.K1202fs) and in LUSC (p.V3082fs), were not found in ClinVar [ref. 45]. While VHL p.C162F lacks a ClinVar record, the co-localizing p.C162W showed three reports of pathogenicity and one report of uncertain significance.

We also investigated the presence of the six predisposing variants in the East Asian ancestry from the gnomAD non-cancer dataset. Only the POLE p.Y1078fs (AC/AN = 1/17,692, AF = 0.0056%) and BRIP1 p.E1222fs (AC/AN = 11/19,232, AF = 0.057%) were present exclusively in the East Asian ancestry of gnomAD-non-cancer dataset. All other East Asian-ancestry variants were not detected in this dataset. Of note, none of the six variants were previously reported in ClinVar [ref. 45].

Germline-somatic two-hit events

We next examined the two-hit hypothesis, whereby a somatic second hit of the same gene is found in carriers of the germline predisposing variants [ref. 46, ref. 47]. First, we investigated the extent of loss of heterozygosity (LOH) of the predisposing variants using our previously developed statistical test [ref. 38] (the “Methods” section) that compares the variant allele fractions in tumor vs. normal samples. Among the variants observed in the African ancestry, we observed significant LOH (FDR < 0.05) for both truncating variants in SDHB p.R116fs and p.R46* in PCPG (Fig. 3a). Three additional variants exhibited significant LOH, including BRCA2 p.R3128* (LUSC), BRCA2 p.K1202fs (OV), and FH p.S187* (KIRP). We also observed suggestive LOH (FDR < 0.15 or tumor VAF > 0.6) for ATM c.2921+1G>A (PRAD) and BRCA2 p.Y1710fs (OV) (Fig. 3b). Among the six predisposing variants in the East Asian ancestry, only POLE p.E2137* (LIHC) showed significant LOH (Fig. 3a).

As an alternative mechanism of a somatic second hit, we identified three biallelic mutations where the rare germline predisposing variant was coupled with a second somatic mutation of the same gene, all found in African ancestry carriers (labeled in Fig. 2b, Additional file 2: Table S4b). In a PRAD carrier of ATM, the germline p.L2332fs variant was coupled with a somatic p.E2164K mutation; in the KIRC carrier of VHL, the germline p.C162F variant was coupled with somatic p.E186* mutation. In a KIRP carrier of FH, whose FH gene expression is low (Fig. 4a), germline p.S187* variant was coupled with a somatic splice-site mutation c.1390+6T>A. Analysis of RNA from the KIRP tumor revealed that the somatic FH: c.1390+6T>A causes mis-splicing of 27.6% of the transcripts in tumor RNA, as indicated by the number of reads spanning consensus splice site (n = 68) and the new cryptic splice site (n = 26) (case 2 in Fig. 4b). None of the six carriers of the predisposing variants in East Asian ancestry harbored a biallelic somatic mutation. Overall, the assessment of LOH and biallelic mutation supports the variants’ contribution to oncogenesis through the two-hit model.

Expression changes in predisposing genes

To examine the transcriptional effects of the predisposing variants, we investigated the gene expression in tumor samples of the predisposing variant carriers (Fig. 4a). We observed 154 overall and 27 non-European ancestry-specific predisposing variants co-occurring with an extreme expression (> 80% or < 20% in the same cancer cohort) of the respective gene, although the current sample sizes preclude us from discovering significantly associated genes compared to non-carriers within each ancestry-cancer cohort (Additional file 2: Table S5a).

All of the expression-associated variants were germline heterozygous variants at the DNA level. The degree of their variant allele fraction in the tumor RNAseq data (RNA VAF) thus indicates the degree of allelic-specific expression (ASE). The African carriers of SDHB truncating variants p.R116fs (the corresponding gene’s expression ranks at the bottom 0.5 percentile among all PCPG cases [0.5%], RNA VAF = 0.25 and p.R46* (9% in PCGP, RNA VAF = 0.80) showed low SDHB expression. The African carriers of BRCA2 p.Y1710fs (6% in OV, RNA VAF = 0) and p.3082fs (15% in LUSC, RNA VAF = 0) also exhibited low BRCA2 (Fig. 4c). In the OV case, the germline BRCA2 p.Y1710fs is coupled with a somatic LOH event, resulting in nearly complete loss of BRCA2 expression.

Both of the African ancestry carriers of FH predisposing variants, FH p.S187* (2% in KIRP, RNA VAF = 0.13) and FH:c.556-2A>T (2% in KIRP, RNA VAF = 0.50), showed low FH expression. In addition to the biallelic somatic FH:c.1390+6T>A mutation in the carrier of germline FH p.S187* described earlier, we also observed a mis-splicing event in a different case carrying germline FH:c.556-2A>T at the RNA level (case 1 in Fig. 4b).

For other ancestries, the tumor from one predisposing variant carrier of the Native/Latin American ancestry, NF1 p.Y489C, showed low NF1 mRNA expression (2% in BRCA, RNA VAF = 0). Overall, RNA VAF of the majority of protein-truncating variants not accompanied by LOH varied between 0 and 0.25 (Additional file 2: Table S5a), suggesting degradation of the mutant allele.

Many predisposing truncating variants of tumor suppressors are assumed to lead to loss of gene expression through mechanisms such as nonsense-mediated decay (NMD). Using the NMD Classifier [ref. 48], we revealed all frameshift variants found in the African and East Asian ancestries were located in the NMD-competent region (Additional file 1: Fig. S3). These results support that a fraction of predisposing variants likely result in reduced gene products of tumor suppressors in ancestral groups.

Conversely, for the rare tumors with germline variants in oncogenes, the two predisposing RET variants are coupled with elevated RET expression in their African ancestry carriers, including p.C631Y (84% in KIRC) and p.D634Y (91% in PCGP).

Power consideration for predisposing gene discovery

Given the currently limited sample sizes in most of the minority cohorts, we sought to identify the required numbers of samples to discover novel cancer predisposing genes. We performed post hoc power analyses to detect a rare-variant association in an aggregation test using SKAT [ref. 34]. We assumed that a high proportion (80%) of variants are casual when focusing on prioritized predisposing variants in accordance with ACMG/AMP guidelines (Additional file 2: Table S6a, see the “Methods” section) [ref. 26, ref. 27, ref. 32]. The detection of rare variants (AF < 0.01) with moderate effect sizes (odds ratio [OR] > 5) with at least 80% power requires sample sizes exceeding 1000 samples (n = 1014) per cancer type (Additional file 1: Fig. S2A).

The sample size requirement suggests limited power for ancestry-specific analyses using TCGA, one of the largest cancer sequencing cohorts to date. For the largest ancestry subgroup in the study, European-ancestry BRCA cases (n = 811), there is 67% power to detect genes with smaller effect sizes (OR < 3). For all other ancestries, their respective largest cohorts afford inadequate power to detect genes with large effect sizes (OR = 9), including the African ancestry BRCA cohort (n = 180, power = 36%), the East Asian-ancestry LIHC cohort (n = 162, power = 24.5%), and the Native/Latin American-ancestry THCA cohort (n = 11, power = < 1%). As a reference, most known cancer predisposing genes, including ATM, PTEN, STK11, CHEK2, BRIP1, and PALB2, have an estimated OR < 10. BRCA1/BRCA2 are exceptions with an OR > 10 for BRCA, but also show more moderate OR for other cancer types [ref. 49]. Despite limited power, this TCGA study includes threefold more non-European cases (n = 1715) compared to the combined number of samples across 27 published non-TCGA sequencing studies that report race/ethnicity information from cancer cohorts (n = 764 non-Europeans, 10 cancer types) [ref. 9]. Moreover, the majority of these studies focused on somatic alterations, and only a handful reported ancestry-specific germline predisposition (Additional file 2: Table S7).

Standard power analyses have the caveat of assuming various unknown parameters that may be inaccurate. We thus performed a downsampling analysis using two cancer types with at least five significantly associated germline genes in the European-ancestry: pheochromocytoma and paraganglioma (PCPG) and sarcoma (SARC) [ref. 4] (Additional file 1: Fig. S2B, Additional file 2: Table S6b). We found that the sample size requirements differ for each gene and cancer cohort, likely due to varying penetrance. For example, six predisposing genes are discovered in both PCPG (n = 146) and SARC (n = 217) samples of the European ancestry, respectively, at their full cohort size. Upon downsampling the cohort size in half, we found VHL, SDHB, RET, and NF1 to be still associated in 73 PCPG cases, whereas only TP53 remained significantly associated in 108 SARC cases. Even while assuming similar penetrance of the predisposing genes across ancestries, this analysis implicates that the discovery power is still far from saturation for most ancestry-specific cohorts (N < 100). The different predisposition landscapes across cancer types should also be accounted for in future study designs.

Discussion

We report one of the most extensive multi-ancestry investigations of rare cancer predisposing genes to date, encompassing 9899 cancer cases across 33 cancer types. In the African ancestry, our results validated six known predisposing genes and nominated BRCA2 as a potential predisposing gene for LUSC (Fig. 1) previously shown only for Europeans. In the East Asian ancestry, we found predisposing variants affecting BRIP1 in STAD that warrants further investigation. Although the number of germline predisposing variants is small, they were associated with LOH (Fig. 3), biallelic mutations (Fig. 2), and gene expression effects in the tumor samples (Fig. 4), supporting their potential contribution to cancer predisposition in carriers.

In this TCGA cohort, we found multiple significant predisposing genes for the European ancestry and seven for the African ancestry, yet lack cancer cohorts with sufficient testing samples for many other ancestries, including Native/Latin American and South Asian that each constitute a considerable fraction of the US population. Even when tested, this study likely contains false negatives in multiple smaller cancer cohorts, especially those of non-Europeans. To achieve 80% power, the post hoc power calculation showed that the detection of rare variants (AF < 0.01) with moderate effect sizes (OR > 5) requires at least 1014 samples (Additional file 1: Fig. S2), a cohort size larger than any of the TCGA non-European cohorts.

It is necessary to use caution when interpreting the ancestry-specific predisposing gene associations identified herein or previous studies of smaller sample sizes, where a handful of carriers may give rise to the association in a limited cancer cohort. Further, the suggestive associations nominated by the TFT analyses will need to be established by analyses of larger cohorts adjusted for potential confounders. Two of the associations we identified in the African ancestry were also complemented by familial studies [ref. 39, ref. 42], providing further validation. To design future cancer genomics studies, one must note that the power considerations differ for discovering somatic driver genes and germline predisposing genes. Current detection powers have potentially reached saturation in detecting somatically mutated genes for sample sizes in multiple cancer types of TCGA [ref. 4], although racial disparities of the sequencing data could potentially limit the generalizability of findings [ref. 50–ref. 52]. We further highlighted the imbalanced dataset limits power for germline gene discovery in populations under-represented in research studies.

We observed selected predisposing genes shared across ancestries (ex. BRCA2 in BRCA/OV and SDHB in PCPG for both the African and European ancestries). Predisposing variants, on the other hand, are highly ancestry-specific (Fig. 2). Many of the predisposing variants found in the African or East Asian ancestry were not identified in the much larger European-ancestry population of TCGA (n = 8184) or even the gnomAD non-cancer cohort (n = 134,187) or submitted to ClinVar by clinical laboratories assessing patients for cancer predisposition. Rare variant classification and interpretation remain a challenge given the low frequency of observation precluding statistical associations. The identification of ancestry-specific predisposing variants further highlights this challenge in minority groups, where current germline sequencing often results in higher rates of variants of unknown significance (VUSs) [ref. 16].

Personalized medicine provides tailored disease diagnosis and treatment plans based on an individual’s unique genetic profile. The knowledge of different cancer predisposing genes and prevalence across ancestries suggests that we need to provide ancestry-specific interpretations of genetic data. In particular, many of the current guidelines for when genetic testing is recommended rely on the underlying likelihood of identifying a germline variant. Thus, accurate estimates of germline prevalence may alter recommendations for different patient populations. At the current sample sizes for minority cohorts, our study is still limited in power to discover and establish ancestry-specificity of predisposing genes (Additional file 1: Fig. S2). However, we were able to discover many ancestry-specific variants not currently submitted to ClinVar. Further, much of the diverse populations within the USA, not to mention worldwide, still lack representation in existing sequencing cohorts. Ongoing sequencing projects will begin to address this disparity within US populations (e.g., CSER [ref. 17], eMERGEIII [ref. 18], Million Veteran Program [ref. 19], and the All of Us Research Program) and multiple countries in East Asia and Europe [ref. 53]. Yet, many populations, such as the diverse African ancestry [ref. 54], remain underserved although projects like H3Africa are designed to address this problem. Additional efforts will be required to deliver the promise of genome-based precision medicine for all.

TCGA provides a powerful multi-omic sequencing dataset comprising more than ten thousand adult cancer cases [ref. 55, ref. 56]. The dataset is used not only for characterizing somatic mutations and molecular subtypes but also enables studies of rare genetic predisposition and germline-somatic interactions [ref. 20, ref. 38, ref. 57–ref. 59]. However, in such applications, one needs to note that TCGA is not a prospective cohort nor designed as a case-control study. Using the matched-ancestry cases of other cancer types as “controls” (the “Methods” section) is not ideal, yet they are the only available samples in the same study. The associations herein, therefore, may show biased effect sizes that require validation in carefully designed epidemiological studies. To enhance the confidence of the reported variants, we focused on identifying their somatic impacts, including LOH, ASE, and extreme gene expression levels that can be uniquely revealed in the multi-omic dataset.

To aid interpretation of low-frequency ancestry-specific variants, evidence of a somatic second hit event (i.e., loss of heterozygosity [LOH] or a biallelic mutation) in tumor samples can support functionality. Our analysis of the two-hit model identified the second somatic events in two thirds (10/15) of the African ancestry-specific predisposing variants and in one out of six of the East Asian ancestry-specific predisposing variants (Additional file 2: Table S4b). Additionally, some carriers of ancestry-specific predisposing variants showed simultaneous extreme expression of the affected genes (Fig. 3). Such evidence derived from analysis of the somatic genome or transcriptome can be further utilized to characterizing rare germline variants [ref. 60], especially when DNA-level analysis still suffers from limited sample sizes.

Our observation of somatic second hit (Figs. 2 and 3) and transcriptional effects (Fig. 4) coupled with germline variants also adds on to the current literature on germline-somatic interactions in cancer [ref. 61]. While the majority of cancer genomic studies focus exclusively on the germline or somatic genome, pathogenic germline variants are associated with different somatic mutational signatures, allele-specific imbalance, or somatic drivers [ref. 20, ref. 38, ref. 58, ref. 62, ref. 63]. The availability of germline DNA analysis and tumor genomic and transcriptomic analyses from the same individual provides critical data to the analyses described here that is not possible in many studies that only analyze germline DNA samples alone. Collectively, these findings are providing the roadmaps of how germline variants may trigger and collaborate with specific somatic mutations, eventually leading to cancer development. In this process, genomes across different ancestral populations provide different contexts for developing somatic mutations and genomic instability, even when the individual carries the same germline predisposition variant. We showcased examples of predisposition-associated LOH and gene expression changes in diverse individuals. As sample sizes of sequencing cohorts expand, analyzing germline-somatic interactions across ancestry will be pivotal to reveal potential ancestry-specific effects.

Conclusions

In summary, we identify ancestry-specific predisposing genes and variants contributing to multiple cancer types. The results provide insights into rare genetic predisposition and their somatic impacts in cases of African and East Asian ancestries. While the identified cancer predisposition genes are known, most predisposing variants are found to be exclusive within ancestries, supporting the “clan-genomics” hypothesis [ref. 64]. Continuous studies using larger ancestry cohorts will be required to enable adequately powered discovery of predisposing genes and improve genetic screening for diverse populations [ref. 65].

References

1. RL Siegel, KD Miller, A Jemal. Cancer statistics, 2018. CA Cancer J Clin, 2018. [PubMed]
2. AM Noone, N Howlader, M Krapcho, D Miller, A Brest, M Yu. SEER cancer statistics review, 2018
3. AW Kurian. BRCA1 and BRCA2 mutations across race and ethnicity: distribution and clinical implications. Curr Opin Obstet Gynecol, 2010. [PubMed]
4. MS Lawrence, P Stojanov, CH Mermel, JT Robinson, LA Garraway, TR Golub. Discovery and saturation analysis of cancer genes across 21 tumour types. Nature, 2014. [PubMed]
5. D Huo, H Hu, SK Rhie, ER Gamazon, AD Cherniack, J Liu. Comparison of breast cancer molecular features and survival by African and European ancestry in The Cancer Genome Atlas. JAMA Oncol., 2017. [PubMed]
6. DF Easton, KA Pooley, AM Dunning, PDP Pharoah, D Thompson, DG Ballinger. Genome-wide association study identifies novel breast cancer susceptibility loci. Nature., 2007. [PubMed]
7. W Zheng, B Zhang, Q Cai, H Sung, K Michailidou, J Shi. Common genetic determinants of breast-cancer risk in East Asian women: a collaborative study of 23 637 breast cancer cases and 25 579 controls. Hum Mol Genet, 2013. [PubMed]
8. D Huo, Y Feng, S Haddad, Y Zheng, S Yao, Y-J Han. Genome-wide association studies in women of African ancestry identified 3q26.21 as a novel susceptibility locus for oestrogen receptor negative breast cancer. Hum Mol Genet, 2016. [PubMed]
9. Adrienne Nugent, Kelly R. Conatser, Llaran L. Turner, James T. Nugent, Esther May B. Sarino, Luisel J. Ricks-Santi. Reporting of race in genome and exome sequencing studies of cancer: a scoping review of the literature. Genetics in Medicine, 2019. [PubMed]
10. J Lilyquist, KJ Ruddy, CM Vachon, FJ Couch. Common genetic variation and breast cancer risk—past, present, and future. Cancer Epidemiol Prev Biomark, 2018
11. FJ Couch, H Shimelis, C Hu, SN Hart, EC Polley, J Na. Associations between cancer predisposition testing panel genes and breast cancer. JAMA Oncol., 2017. [PubMed]
12. JE Churpek, T Walsh, Y Zheng, Z Moton, AM Thornton, MK Lee. Inherited predisposition to breast cancer among African American women. Breast Cancer Res Treat, 2015. [PubMed]
13. JD Fackenthal, J Zhang, B Zhang, Y Zheng, F Hagos, DR Burrill. High prevalence of BRCA1 and BRCA2 mutations in unselected Nigerian breast cancer patients. Int J Cancer, 2012. [PubMed]
14. B Newman, H Mu, LM Butler, RC Millikan, PG Moorman, MC King. Frequency of breast cancer attributable to BRCA1 in a population-based series of American women. JAMA., 1998. [PubMed]
15. EL Schubert, MK Lee, HC Mefford, RH Argonza, JE Morrow, J Hull. BRCA2 in American families with four or more cases of breast or ovarian cancer: recurrent and novel mutations, variable expression, penetrance, and the possibility of families whose cancer is not attributable to BRCA1 or BRCA2. Am J Hum Genet, 1997. [PubMed]
16. JL Caswell-Jin, T Gupta, E Hall, IM Petrovchich, MA Mills, KE Kingham. Racial/ethnic differences in multiple-gene sequencing results for hereditary cancer risk. Genet Med, 2018. [PubMed]
17. LM Amendola, JS Berg, CR Horowitz, F Angelo, JT Bensen, BB Biesecker. The clinical sequencing evidence-generating research consortium: integrating genomic sequencing in diverse and medically underserved populations. Am J Hum Genet, 2018. [PubMed]
18. 18.Harmonizing Clinical Sequencing and Interpretation for the eMERGE III Network. Am J Hum Genet. 2019;105:588–605.
19. JM Gaziano, J Concato, M Brophy, L Fiore, S Pyarajan, J Breeling. Million Veteran Program: a mega-biobank to study genetic influences on health and disease. J Clin Epidemiol, 2016. [PubMed]
20. Kuan-lin Huang, R. Jay Mashl, Yige Wu, Deborah I. Ritter, Jiayin Wang, Clara Oh, Marta Paczkowska, Sheila Reynolds, Matthew A. Wyczalkowski, Ninad Oak, Adam D. Scott, Michal Krassowski, Andrew D. Cherniack, Kathleen E. Houlahan, Reyka Jayasinghe, Liang-Bo Wang, Daniel Cui Zhou, Di Liu, Song Cao, Young Won Kim, Amanda Koire, Joshua F. McMichael, Vishwanathan Hucthagowder, Tae-Beom Kim, Abigail Hahn, Chen Wang, Michael D. McLellan, Fahd Al-Mulla, Kimberly J. Johnson, Olivier Lichtarge, Paul C. Boutros, Benjamin Raphael, Alexander J. Lazar, Wei Zhang, Michael C. Wendl, Ramaswamy Govindan, Sanjay Jain, David Wheeler, Shashikant Kulkarni, John F. Dipersio, Jüri Reimand, Funda Meric-Bernstam, Ken Chen, Ilya Shmulevich, Sharon E. Plon, Feng Chen, Li Ding, Samantha J. Caesar-Johnson, John A. Demchok, Ina Felau, Melpomeni Kasapi, Martin L. Ferguson, Carolyn M. Hutter, Heidi J. Sofia, Roy Tarnuzzer, Zhining Wang, Liming Yang, Jean C. Zenklusen, Jiashan (Julia) Zhang, Sudha Chudamani, Jia Liu, Laxmi Lolla, Rashi Naresh, Todd Pihl, Qiang Sun, Yunhu Wan, Ye Wu, Juok Cho, Timothy DeFreitas, Scott Frazer, Nils Gehlenborg, Gad Getz, David I. Heiman, Jaegil Kim, Michael S. Lawrence, Pei Lin, Sam Meier, Michael S. Noble, Gordon Saksena, Doug Voet, Hailei Zhang, Brady Bernard, Nyasha Chambwe, Varsha Dhankani, Theo Knijnenburg, Roger Kramer, Kalle Leinonen, Yuexin Liu, Michael Miller, Sheila Reynolds, Ilya Shmulevich, Vesteinn Thorsson, Wei Zhang, Rehan Akbani, Bradley M. Broom, Apurva M. Hegde, Zhenlin Ju, Rupa S. Kanchi, Anil Korkut, Jun Li, Han Liang, Shiyun Ling, Wenbin Liu, Yiling Lu, Gordon B. Mills, Kwok-Shing Ng, Arvind Rao, Michael Ryan, Jing Wang, John N. Weinstein, Jiexin Zhang, Adam Abeshouse, Joshua Armenia, Debyani Chakravarty, Walid K. Chatila, Ino de Bruijn, Jianjiong Gao, Benjamin E. Gross, Zachary J. Heins, Ritika Kundra, Konnor La, Marc Ladanyi, Augustin Luna, Moriah G. Nissan, Angelica Ochoa, Sarah M. Phillips, Ed Reznik, Francisco Sanchez-Vega, Chris Sander, Nikolaus Schultz, Robert Sheridan, S. Onur Sumer, Yichao Sun, Barry S. Taylor, Jioajiao Wang, Hongxin Zhang, Pavana Anur, Myron Peto, Paul Spellman, Christopher Benz, Joshua M. Stuart, Christopher K. Wong, Christina Yau, D. Neil Hayes, Joel S. Parker, Matthew D. Wilkerson, Adrian Ally, Miruna Balasundaram, Reanne Bowlby, Denise Brooks, Rebecca Carlsen, Eric Chuah, Noreen Dhalla, Robert Holt, Steven J.M. Jones, Katayoon Kasaian, Darlene Lee, Yussanne Ma, Marco A. Marra, Michael Mayo, Richard A. Moore, Andrew J. Mungall, Karen Mungall, A. Gordon Robertson, Sara Sadeghi, Jacqueline E. Schein, Payal Sipahimalani, Angela Tam, Nina Thiessen, Kane Tse, Tina Wong, Ashton C. Berger, Rameen Beroukhim, Andrew D. Cherniack, Carrie Cibulskis, Stacey B. Gabriel, Galen F. Gao, Gavin Ha, Matthew Meyerson, Steven E. Schumacher, Juliann Shih, Melanie H. Kucherlapati, Raju S. Kucherlapati, Stephen Baylin, Leslie Cope, Ludmila Danilova, Moiz S. Bootwalla, Phillip H. Lai, Dennis T. Maglinte, David J. Van Den Berg, Daniel J. Weisenberger, J. Todd Auman, Saianand Balu, Tom Bodenheimer, Cheng Fan, Katherine A. Hoadley, Alan P. Hoyle, Stuart R. Jefferys, Corbin D. Jones, Shaowu Meng, Piotr A. Mieczkowski, Lisle E. Mose, Amy H. Perou, Charles M. Perou, Jeffrey Roach, Yan Shi, Janae V. Simons, Tara Skelly, Matthew G. Soloway, Donghui Tan, Umadevi Veluvolu, Huihui Fan, Toshinori Hinoue, Peter W. Laird, Hui Shen, Wanding Zhou, Michelle Bellair, Kyle Chang, Kyle Covington, Chad J. Creighton, Huyen Dinh, HarshaVardhan Doddapaneni, Lawrence A. Donehower, Jennifer Drummond, Richard A. Gibbs, Robert Glenn, Walker Hale, Yi Han, Jianhong Hu, Viktoriya Korchina, Sandra Lee, Lora Lewis, Wei Li, Xiuping Liu, Margaret Morgan, Donna Morton, Donna Muzny, Jireh Santibanez, Margi Sheth, Eve Shinbrot, Linghua Wang, Min Wang, David A. Wheeler, Liu Xi, Fengmei Zhao, Julian Hess, Elizabeth L. Appelbaum, Matthew Bailey, Matthew G. Cordes, Li Ding, Catrina C. Fronick, Lucinda A. Fulton, Robert S. Fulton, Cyriac Kandoth, Elaine R. Mardis, Michael D. McLellan, Christopher A. Miller, Heather K. Schmidt, Richard K. Wilson, Daniel Crain, Erin Curley, Johanna Gardner, Kevin Lau, David Mallery, Scott Morris, Joseph Paulauskis, Robert Penny, Candace Shelton, Troy Shelton, Mark Sherman, Eric Thompson, Peggy Yena, Jay Bowen, Julie M. Gastier-Foster, Mark Gerken, Kristen M. Leraas, Tara M. Lichtenberg, Nilsa C. Ramirez, Lisa Wise, Erik Zmuda, Niall Corcoran, Tony Costello, Christopher Hovens, Andre L. Carvalho, Ana C. de Carvalho, José H. Fregnani, Adhemar Longatto-Filho, Rui M. Reis, Cristovam Scapulatempo-Neto, Henrique C.S. Silveira, Daniel O. Vidal, Andrew Burnette, Jennifer Eschbacher, Beth Hermes, Ardene Noss, Rosy Singh, Matthew L. Anderson, Patricia D. Castro, Michael Ittmann, David Huntsman, Bernard Kohl, Xuan Le, Richard Thorp, Chris Andry, Elizabeth R. Duffy, Vladimir Lyadov, Oxana Paklina, Galiya Setdikova, Alexey Shabunin, Mikhail Tavobilov, Christopher McPherson, Ronald Warnick, Ross Berkowitz, Daniel Cramer, Colleen Feltmate, Neil Horowitz, Adam Kibel, Michael Muto, Chandrajit P. Raut, Andrei Malykh, Jill S. Barnholtz-Sloan, Wendi Barrett, Karen Devine, Jordonna Fulop, Quinn T. Ostrom, Kristen Shimmel, Yingli Wolinsky, Andrew E. Sloan, Agostino De Rose, Felice Giuliante, Marc Goodman, Beth Y. Karlan, Curt H. Hagedorn, John Eckman, Jodi Harr, Jerome Myers, Kelinda Tucker, Leigh Anne Zach, Brenda Deyarmin, Hai Hu, Leonid Kvecher, Caroline Larson, Richard J. Mural, Stella Somiari, Ales Vicha, Tomas Zelinka, Joseph Bennett, Mary Iacocca, Brenda Rabeno, Patricia Swanson, Mathieu Latour, Louis Lacombe, Bernard Têtu, Alain Bergeron, Mary McGraw, Susan M. Staugaitis, John Chabot, Hanina Hibshoosh, Antonia Sepulveda, Tao Su, Timothy Wang, Olga Potapova, Olga Voronina, Laurence Desjardins, Odette Mariani, Sergio Roman-Roman, Xavier Sastre, Marc-Henri Stern, Feixiong Cheng, Sabina Signoretti, Andrew Berchuck, Darell Bigner, Eric Lipp, Jeffrey Marks, Shannon McCall, Roger McLendon, Angeles Secord, Alexis Sharp, Madhusmita Behera, Daniel J. Brat, Amy Chen, Keith Delman, Seth Force, Fadlo Khuri, Kelly Magliocca, Shishir Maithel, Jeffrey J. Olson, Taofeek Owonikoko, Alan Pickens, Suresh Ramalingam, Dong M. Shin, Gabriel Sica, Erwin G. Van Meir, Hongzheng Zhang, Wil Eijckenboom, Ad Gillis, Esther Korpershoek, Leendert Looijenga, Wolter Oosterhuis, Hans Stoop, Kim E. van Kessel, Ellen C. Zwarthoff, Chiara Calatozzolo, Lucia Cuppini, Stefania Cuzzubbo, Francesco DiMeco, Gaetano Finocchiaro, Luca Mattei, Alessandro Perin, Bianca Pollo, Chu Chen, John Houck, Pawadee Lohavanichbutr, Arndt Hartmann, Christine Stoehr, Robert Stoehr, Helge Taubert, Sven Wach, Bernd Wullich, Witold Kycler, Dawid Murawa, Maciej Wiznerowicz, Ki Chung, W. Jeffrey Edenfield, Julie Martin, Eric Baudin, Glenn Bubley, Raphael Bueno, Assunta De Rienzo, William G. Richards, Steven Kalkanis, Tom Mikkelsen, Houtan Noushmehr, Lisa Scarpace, Nicolas Girard, Marta Aymerich, Elias Campo, Eva Giné, Armando López Guillermo, Nguyen Van Bang, Phan Thi Hanh, Bui Duc Phu, Yufang Tang, Howard Colman, Kimberley Evason, Peter R. Dottino, John A. Martignetti, Hani Gabra, Hartmut Juhl, Teniola Akeredolu, Serghei Stepa, Dave Hoon, Keunsoo Ahn, Koo Jeong Kang, Felix Beuschlein, Anne Breggia, Michael Birrer, Debra Bell, Mitesh Borad, Alan H. Bryce, Erik Castle, Vishal Chandan, John Cheville, John A. Copland, Michael Farnell, Thomas Flotte, Nasra Giama, Thai Ho, Michael Kendrick, Jean-Pierre Kocher, Karla Kopp, Catherine Moser, David Nagorney, Daniel O’Brien, Brian Patrick O’Neill, Tushar Patel, Gloria Petersen, Florencia Que, Michael Rivera, Lewis Roberts, Robert Smallridge, Thomas Smyrk, Melissa Stanton, R. Houston Thompson, Michael Torbenson, Ju Dong Yang, Lizhi Zhang, Fadi Brimo, Jaffer A. Ajani, Ana Maria Angulo Gonzalez, Carmen Behrens, Jolanta Bondaruk, Russell Broaddus, Bogdan Czerniak, Bita Esmaeli, Junya Fujimoto, Jeffrey Gershenwald, Charles Guo, Alexander J. Lazar, Christopher Logothetis, Funda Meric-Bernstam, Cesar Moran, Lois Ramondetta, David Rice, Anil Sood, Pheroze Tamboli, Timothy Thompson, Patricia Troncoso, Anne Tsao, Ignacio Wistuba, Candace Carter, Lauren Haydu, Peter Hersey, Valerie Jakrot, Hojabr Kakavand, Richard Kefford, Kenneth Lee, Georgina Long, Graham Mann, Michael Quinn, Robyn Saw, Richard Scolyer, Kerwin Shannon, Andrew Spillane, Jonathan Stretch, Maria Synott, John Thompson, James Wilmott, Hikmat Al-Ahmadie, Timothy A. Chan, Ronald Ghossein, Anuradha Gopalan, Douglas A. Levine, Victor Reuter, Samuel Singer, Bhuvanesh Singh, Nguyen Viet Tien, Thomas Broudy, Cyrus Mirsaidi, Praveen Nair, Paul Drwiega, Judy Miller, Jennifer Smith, Howard Zaren, Joong-Won Park, Nguyen Phi Hung, Electron Kebebew, W. Marston Linehan, Adam R. Metwalli, Karel Pacak, Peter A. Pinto, Mark Schiffman, Laura S. Schmidt, Cathy D. Vocke, Nicolas Wentzensen, Robert Worrell, Hannah Yang, Marc Moncrieff, Chandra Goparaju, Jonathan Melamed, Harvey Pass, Natalia Botnariuc, Irina Caraman, Mircea Cernat, Inga Chemencedji, Adrian Clipca, Serghei Doruc, Ghenadie Gorincioi, Sergiu Mura, Maria Pirtac, Irina Stancul, Diana Tcaciuc, Monique Albert, Iakovina Alexopoulou, Angel Arnaout, John Bartlett, Jay Engel, Sebastien Gilbert, Jeremy Parfitt, Harman Sekhon, George Thomas, Doris M. Rassl, Robert C. Rintoul, Carlo Bifulco, Raina Tamakawa, Walter Urba, Nicholas Hayward, Henri Timmers, Anna Antenucci, Francesco Facciolo, Gianluca Grazi, Mirella Marino, Roberta Merola, Ronald de Krijger, Anne-Paule Gimenez-Roqueplo, Alain Piché, Simone Chevalier, Ginette McKercher, Kivanc Birsoy, Gene Barnett, Cathy Brewer, Carol Farver, Theresa Naska, Nathan A. Pennell, Daniel Raymond, Cathy Schilero, Kathy Smolenski, Felicia Williams, Carl Morrison, Jeffrey A. Borgia, Michael J. Liptay, Mark Pool, Christopher W. Seder, Kerstin Junker, Larsson Omberg, Mikhail Dinkin, George Manikhas, Domenico Alvaro, Maria Consiglia Bragazzi, Vincenzo Cardinale, Guido Carpino, Eugenio Gaudio, David Chesla, Sandra Cottingham, Michael Dubina, Fedor Moiseenko, Renumathy Dhanasekaran, Karl-Friedrich Becker, Klaus-Peter Janssen, Julia Slotta-Huspenina, Mohamed H. Abdel-Rahman, Dina Aziz, Sue Bell, Colleen M. Cebulla, Amy Davis, Rebecca Duell, J. Bradley Elder, Joe Hilty, Bahavna Kumar, James Lang, Norman L. Lehman, Randy Mandt, Phuong Nguyen, Robert Pilarski, Karan Rai, Lynn Schoenfield, Kelly Senecal, Paul Wakely, Paul Hansen, Ronald Lechan, James Powers, Arthur Tischler, William E. Grizzle, Katherine C. Sexton, Alison Kastl, Joel Henderson, Sima Porten, Jens Waldmann, Martin Fassnacht, Sylvia L. Asa, Dirk Schadendorf, Marta Couce, Markus Graefen, Hartwig Huland, Guido Sauter, Thorsten Schlomm, Ronald Simon, Pierre Tennstedt, Oluwole Olabode, Mark Nelson, Oliver Bathe, Peter R. Carroll, June M. Chan, Philip Disaia, Pat Glenn, Robin K. Kelley, Charles N. Landen, Joanna Phillips, Michael Prados, Jeffry Simko, Karen Smith-McCune, Scott VandenBerg, Kevin Roggin, Ashley Fehrenbach, Ady Kendler, Suzanne Sifri, Ruth Steele, Antonio Jimeno, Francis Carey, Ian Forgie, Massimo Mannelli, Michael Carney, Brenda Hernandez, Benito Campos, Christel Herold-Mende, Christin Jungk, Andreas Unterberg, Andreas von Deimling, Aaron Bossler, Joseph Galbraith, Laura Jacobus, Michael Knudson, Tina Knutson, Deqin Ma, Mohammed Milhem, Rita Sigmund, Andrew K. Godwin, Rashna Madan, Howard G. Rosenthal, Clement Adebamowo, Sally N. Adebamowo, Alex Boussioutas, David Beer, Thomas Giordano, Anne-Marie Mes-Masson, Fred Saad, Therese Bocklage, Lisa Landrum, Robert Mannel, Kathleen Moore, Katherine Moxley, Russel Postier, Joan Walker, Rosemary Zuna, Michael Feldman, Federico Valdivieso, Rajiv Dhir, James Luketich, Edna M. Mora Pinero, Mario Quintero-Aguilo, Carlos Gilberto Carlotti, Jose Sebastião Dos Santos, Rafael Kemp, Ajith Sankarankuty, Daniela Tirapelli, James Catto, Kathy Agnew, Elizabeth Swisher, Jenette Creaney, Bruce Robinson, Carl Simon Shelley, Eryn M. Godwin, Sara Kendall, Cassaundra Shipman, Carol Bradford, Thomas Carey, Andrea Haddad, Jeffey Moyer, Lisa Peterson, Mark Prince, Laura Rozek, Gregory Wolf, Rayleen Bowman, Kwun M. Fong, Ian Yang, Robert Korst, W. Kimryn Rathmell, J. Leigh Fantacone-Campbell, Jeffrey A. Hooke, Albert J. Kovatich, Craig D. Shriver, John DiPersio, Bettina Drake, Ramaswamy Govindan, Sharon Heath, Timothy Ley, Brian Van Tine, Peter Westervelt, Mark A. Rubin, Jung Il Lee, Natália D. Aredes, Armaz Mariamidze. Pathogenic Germline Variants in 10,389 Adult Cancers. Cell, 2018. [PubMed]
21. Jian Carrot-Zhang, Nyasha Chambwe, Jeffrey S. Damrauer, Theo A. Knijnenburg, A. Gordon Robertson, Christina Yau, Wanding Zhou, Ashton C. Berger, Kuan-lin Huang, Justin Y. Newberg, R. Jay Mashl, Alessandro Romanel, Rosalyn W. Sayaman, Francesca Demichelis, Ina Felau, Garrett M. Frampton, Seunghun Han, Katherine A. Hoadley, Anab Kemal, Peter W. Laird, Alexander J. Lazar, Xiuning Le, Ninad Oak, Hui Shen, Christopher K. Wong, Jean C. Zenklusen, Elad Ziv, Andrew D. Cherniack, Rameen Beroukhim, Francois Aguet, Li Ding, John A. Demchok, Michael K.A. Mensah, Samantha Caesar-Johnson, Roy Tarnuzzer, Zhining Wang, Liming Yang, Jessica Alfoldi, Konrad J. Karczewski, Daniel G. MacArthur, Matthew Meyerson, Christopher Benz, Joshua M. Stuart. Comprehensive Analysis of Genetic Ancestry and Its Molecular Correlates in Cancer. Cancer Cell, 2020. [PubMed]
22. DH Alexander, J Novembre, K Lange. Fast model-based estimation of ancestry in unrelated individuals. Genome Res, 2009. [PubMed]
23. DC Koboldt, Q Zhang, DE Larson, D Shen, MD McLellan, L Lin. VarScan 2: somatic mutation and copy number alteration discovery in cancer by exome sequencing. Genome Res, 2012. [PubMed]
24. AH McKenna, M Hanna, E Banks, A Sivachenko, K Cibulskis, A Kernytsky. The Genome Analysis Toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data. Genome Res, 2010. [PubMed]
25. K Ye, MH Schulz, Q Long, R Apweiler, Z Ning. Pindel: a pattern growth approach to detect break points of large deletions and medium sized insertions from paired-end short reads. Bioinformatics., 2009. [PubMed]
26. Adam D Scott, Kuan-Lin Huang, Amila Weerasinghe, R Jay Mashl, Qingsong Gao, Fernanda Martins Rodrigues, Matthew A Wyczalkowski, Li Ding. CharGer: clinical Characterization of Germline variants. Bioinformatics, 2018
27. S Richards, N Aziz, S Bale, D Bick, S Das, J Gastier-Foster. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med., 2015. [PubMed]
28. Shaun Purcell, Benjamin Neale, Kathe Todd-Brown, Lori Thomas, Manuel A.R. Ferreira, David Bender, Julian Maller, Pamela Sklar, Paul I.W. de Bakker, Mark J. Daly, Pak C. Sham. PLINK: A Tool Set for Whole-Genome Association and Population-Based Linkage Analyses. The American Journal of Human Genetics, 2007. [PubMed]
29. S Basu, W Pan. Comparison of statistical tests for disease association with rare variants. Genet Epidemiol, 2011. [PubMed]
30. 30.Karczewski KJ, Francioli LC, Tiao G, Cummings BB, Alföldi J, Wang Q, et al. Variation across 141,456 human exomes and genomes reveals the spectrum of loss-of-function intolerance across human protein-coding genes. bioRxiv. 2019;531210. 10.1101/531210.
31. 31.Lek M, Karczewski KJ, Samocha KE, Banks E, Fennell T, O AH, et al. Analysis of protein-coding genetic variation in 60,706 humans. Nature. 2015;536:285–291.
32. Quan Li, Kai Wang. InterVar: Clinical Interpretation of Genetic Variants by the 2015 ACMG-AMP Guidelines. The American Journal of Human Genetics, 2017. [PubMed]
33. K Wang, M Li, H Hakonarson. ANNOVAR: functional annotation of genetic variants from high-throughput sequencing data. Nucleic Acids Res, 2010. [PubMed]
34. MC Wu, S Lee, T Cai, Y Li, M Boehnke, X Lin. Rare-variant association testing for sequencing data with the sequence kernel association test. Am J Hum Genet, 2011. [PubMed]
35. Myvizhi Esai Selvan, Robert J. Klein, Zeynep H. Gümüş. Rare, Pathogenic Germline Variants in Fanconi Anemia Genes Increase Risk for Squamous Lung Cancer. Clinical Cancer Research, 2018. [PubMed]
36. Y Wang, JD McKay, T Rafnar, Z Wang, MN Timofeeva, P Broderick. Rare variants of large effect in BRCA2 and CHEK2 affect risk of lung cancer. Nat Genet, 2014. [PubMed]
37. SA Gayther, J Mangion, P Russell, S Seal, R Barfoot, BAJ Ponder. Variation of risks of breast and ovarian cancer associated with different germline mutations of the BRCA2 gene. Nat Genet, 1997. [PubMed]
38. C Lu, M Xie, MC Wendl, J Wang, MD McLellan, MDM Leiserson. Patterns and functional implications of rare germline variants across 12 cancer types. Nat Commun, 2015. [PubMed]
39. S Majumdar, CA Friedrich, CA Koch, GC Megason, JD Fratkin, GW Moll. Compound heterozygous mutation with a novel splice donor region DNA sequence variant in the succinate dehydrogenase subunit B gene in malignant paraganglioma. Pediatr Blood Cancer, 2010. [PubMed]
40. JL Beebe-Dimmer, KA Zuhlke, AM Johnson, D Liesman, KA Cooney. Rare germline mutations in African American men diagnosed with early-onset prostate cancer. Prostate, 2018. [PubMed]
41. R Na, SL Zheng, M Han, H Yu, D Jiang, S Shah. Germline mutations in ATM and BRCA1/2 distinguish risk for lethal and indolent prostate cancer and are associated with early age at death. Eur Urol, 2017. [PubMed]
42. M-H Wei, O Toure, GM Glenn, M Pithukpakorn, L Neckers, C Stolle. Novel mutations in FH and expansion of the spectrum of phenotypes expressed in families with hereditary leiomyomatosis and renal cell cancer. J Med Genet, 2006. [PubMed]
43. B Krishnan, TL Rose, J Kardos, MI Milowsky, WY Kim. Intrinsic genomic differences between African American and white patients with clear cell renal cell carcinoma. JAMA Oncol, 2016. [PubMed]
44. J Sutton, MS Orloff, C Michener, A Chiesa-Vottero, R Prayson, AS Nowacki. Association of specific PTEN/10q haplotypes with endometrial cancer phenotypes in African-American and European American women. Gynecol Oncol, 2015. [PubMed]
45. Melissa J Landrum, Jennifer M Lee, Mark Benson, Garth R Brown, Chen Chao, Shanmuga Chitipiralla, Baoshan Gu, Jennifer Hart, Douglas Hoffman, Wonhee Jang, Karen Karapetyan, Kenneth Katz, Chunlei Liu, Zenith Maddipatla, Adriana Malheiro, Kurt McDaniel, Michael Ovetsky, George Riley, George Zhou, J Bradley Holmes, Brandi L Kattman, Donna R Maglott. ClinVar: improving access to variant interpretations and supporting evidence. Nucleic Acids Research, 2017
46. A. G. Knudson. Mutation and Cancer: Statistical Study of Retinoblastoma. Proceedings of the National Academy of Sciences, 1971
47. Alfred G. Knudson. Two genetic hits (more or less) to cancer. Nature Reviews Cancer, 2001. [PubMed]
48. Min-Kung Hsu, Hsuan-Yu Lin, Feng-Chi Chen. NMD Classifier: A reliable and systematic classification tool for nonsense-mediated decay events. PLOS ONE, 2017. [PubMed]
49. Clare Turnbull, Nazneen Rahman. Genetic Predisposition to Breast Cancer: Past, Present, and Future. Annual Review of Genomics and Human Genetics, 2008. [PubMed]
50. Daniel E. Spratt, Tiffany Chan, Levi Waldron, Corey Speers, Felix Y. Feng, Olorunseun O. Ogunwobi, Joseph R. Osborne. Racial/Ethnic Disparities in Genomic Sequencing. JAMA Oncology, 2016. [PubMed]
51. Ashton C. Berger, Anil Korkut, Rupa S. Kanchi, Apurva M. Hegde, Walter Lenoir, Wenbin Liu, Yuexin Liu, Huihui Fan, Hui Shen, Visweswaran Ravikumar, Arvind Rao, Andre Schultz, Xubin Li, Pavel Sumazin, Cecilia Williams, Pieter Mestdagh, Preethi H. Gunaratne, Christina Yau, Reanne Bowlby, A. Gordon Robertson, Daniel G. Tiezzi, Chen Wang, Andrew D. Cherniack, Andrew K. Godwin, Nicole M. Kuderer, Janet S. Rader, Rosemary E. Zuna, Anil K. Sood, Alexander J. Lazar, Akinyemi I. Ojesina, Clement Adebamowo, Sally N. Adebamowo, Keith A. Baggerly, Ting-Wen Chen, Hua-Sheng Chiu, Steve Lefever, Liang Liu, Karen MacKenzie, Sandra Orsulic, Jason Roszik, Carl Simon Shelley, Qianqian Song, Christopher P. Vellano, Nicolas Wentzensen, John N. Weinstein, Gordon B. Mills, Douglas A. Levine, Rehan Akbani, Samantha J. Caesar-Johnson, John A. Demchok, Ina Felau, Melpomeni Kasapi, Martin L. Ferguson, Carolyn M. Hutter, Heidi J. Sofia, Roy Tarnuzzer, Zhining Wang, Liming Yang, Jean C. Zenklusen, Jiashan (Julia) Zhang, Sudha Chudamani, Jia Liu, Laxmi Lolla, Rashi Naresh, Todd Pihl, Qiang Sun, Yunhu Wan, Ye Wu, Juok Cho, Timothy DeFreitas, Scott Frazer, Nils Gehlenborg, Gad Getz, David I. Heiman, Jaegil Kim, Michael S. Lawrence, Pei Lin, Sam Meier, Michael S. Noble, Gordon Saksena, Doug Voet, Hailei Zhang, Brady Bernard, Nyasha Chambwe, Varsha Dhankani, Theo Knijnenburg, Roger Kramer, Kalle Leinonen, Yuexin Liu, Michael Miller, Sheila Reynolds, Ilya Shmulevich, Vesteinn Thorsson, Wei Zhang, Rehan Akbani, Bradley M. Broom, Apurva M. Hegde, Zhenlin Ju, Rupa S. Kanchi, Anil Korkut, Jun Li, Han Liang, Shiyun Ling, Wenbin Liu, Yiling Lu, Gordon B. Mills, Kwok-Shing Ng, Arvind Rao, Michael Ryan, Jing Wang, John N. Weinstein, Jiexin Zhang, Adam Abeshouse, Joshua Armenia, Debyani Chakravarty, Walid K. Chatila, Ino de Bruijn, Jianjiong Gao, Benjamin E. Gross, Zachary J. Heins, Ritika Kundra, Konnor La, Marc Ladanyi, Augustin Luna, Moriah G. Nissan, Angelica Ochoa, Sarah M. Phillips, Ed Reznik, Francisco Sanchez-Vega, Chris Sander, Nikolaus Schultz, Robert Sheridan, S. Onur Sumer, Yichao Sun, Barry S. Taylor, Jioajiao Wang, Hongxin Zhang, Pavana Anur, Myron Peto, Paul Spellman, Christopher Benz, Joshua M. Stuart, Christopher K. Wong, Christina Yau, D. Neil Hayes, Joel S. Parker, Matthew D. Wilkerson, Adrian Ally, Miruna Balasundaram, Reanne Bowlby, Denise Brooks, Rebecca Carlsen, Eric Chuah, Noreen Dhalla, Robert Holt, Steven J.M. Jones, Katayoon Kasaian, Darlene Lee, Yussanne Ma, Marco A. Marra, Michael Mayo, Richard A. Moore, Andrew J. Mungall, Karen Mungall, A. Gordon Robertson, Sara Sadeghi, Jacqueline E. Schein, Payal Sipahimalani, Angela Tam, Nina Thiessen, Kane Tse, Tina Wong, Ashton C. Berger, Rameen Beroukhim, Andrew D. Cherniack, Carrie Cibulskis, Stacey B. Gabriel, Galen F. Gao, Gavin Ha, Matthew Meyerson, Steven E. Schumacher, Juliann Shih, Melanie H. Kucherlapati, Raju S. Kucherlapati, Stephen Baylin, Leslie Cope, Ludmila Danilova, Moiz S. Bootwalla, Phillip H. Lai, Dennis T. Maglinte, David J. Van Den Berg, Daniel J. Weisenberger, J. Todd Auman, Saianand Balu, Tom Bodenheimer, Cheng Fan, Katherine A. Hoadley, Alan P. Hoyle, Stuart R. Jefferys, Corbin D. Jones, Shaowu Meng, Piotr A. Mieczkowski, Lisle E. Mose, Amy H. Perou, Charles M. Perou, Jeffrey Roach, Yan Shi, Janae V. Simons, Tara Skelly, Matthew G. Soloway, Donghui Tan, Umadevi Veluvolu, Huihui Fan, Toshinori Hinoue, Peter W. Laird, Hui Shen, Wanding Zhou, Michelle Bellair, Kyle Chang, Kyle Covington, Chad J. Creighton, Huyen Dinh, HarshaVardhan Doddapaneni, Lawrence A. Donehower, Jennifer Drummond, Richard A. Gibbs, Robert Glenn, Walker Hale, Yi Han, Jianhong Hu, Viktoriya Korchina, Sandra Lee, Lora Lewis, Wei Li, Xiuping Liu, Margaret Morgan, Donna Morton, Donna Muzny, Jireh Santibanez, Margi Sheth, Eve Shinbrot, Linghua Wang, Min Wang, David A. Wheeler, Liu Xi, Fengmei Zhao, Julian Hess, Elizabeth L. Appelbaum, Matthew Bailey, Matthew G. Cordes, Li Ding, Catrina C. Fronick, Lucinda A. Fulton, Robert S. Fulton, Cyriac Kandoth, Elaine R. Mardis, Michael D. McLellan, Christopher A. Miller, Heather K. Schmidt, Richard K. Wilson, Daniel Crain, Erin Curley, Johanna Gardner, Kevin Lau, David Mallery, Scott Morris, Joseph Paulauskis, Robert Penny, Candace Shelton, Troy Shelton, Mark Sherman, Eric Thompson, Peggy Yena, Jay Bowen, Julie M. Gastier-Foster, Mark Gerken, Kristen M. Leraas, Tara M. Lichtenberg, Nilsa C. Ramirez, Lisa Wise, Erik Zmuda, Niall Corcoran, Tony Costello, Christopher Hovens, Andre L. Carvalho, Ana C. de Carvalho, José H. Fregnani, Adhemar Longatto-Filho, Rui M. Reis, Cristovam Scapulatempo-Neto, Henrique C.S. Silveira, Daniel O. Vidal, Andrew Burnette, Jennifer Eschbacher, Beth Hermes, Ardene Noss, Rosy Singh, Matthew L. Anderson, Patricia D. Castro, Michael Ittmann, David Huntsman, Bernard Kohl, Xuan Le, Richard Thorp, Chris Andry, Elizabeth R. Duffy, Vladimir Lyadov, Oxana Paklina, Galiya Setdikova, Alexey Shabunin, Mikhail Tavobilov, Christopher McPherson, Ronald Warnick, Ross Berkowitz, Daniel Cramer, Colleen Feltmate, Neil Horowitz, Adam Kibel, Michael Muto, Chandrajit P. Raut, Andrei Malykh, Jill S. Barnholtz-Sloan, Wendi Barrett, Karen Devine, Jordonna Fulop, Quinn T. Ostrom, Kristen Shimmel, Yingli Wolinsky, Andrew E. Sloan, Agostino De Rose, Felice Giuliante, Marc Goodman, Beth Y. Karlan, Curt H. Hagedorn, John Eckman, Jodi Harr, Jerome Myers, Kelinda Tucker, Leigh Anne Zach, Brenda Deyarmin, Hai Hu, Leonid Kvecher, Caroline Larson, Richard J. Mural, Stella Somiari, Ales Vicha, Tomas Zelinka, Joseph Bennett, Mary Iacocca, Brenda Rabeno, Patricia Swanson, Mathieu Latour, Louis Lacombe, Bernard Têtu, Alain Bergeron, Mary McGraw, Susan M. Staugaitis, John Chabot, Hanina Hibshoosh, Antonia Sepulveda, Tao Su, Timothy Wang, Olga Potapova, Olga Voronina, Laurence Desjardins, Odette Mariani, Sergio Roman-Roman, Xavier Sastre, Marc-Henri Stern, Feixiong Cheng, Sabina Signoretti, Andrew Berchuck, Darell Bigner, Eric Lipp, Jeffrey Marks, Shannon McCall, Roger McLendon, Angeles Secord, Alexis Sharp, Madhusmita Behera, Daniel J. Brat, Amy Chen, Keith Delman, Seth Force, Fadlo Khuri, Kelly Magliocca, Shishir Maithel, Jeffrey J. Olson, Taofeek Owonikoko, Alan Pickens, Suresh Ramalingam, Dong M. Shin, Gabriel Sica, Erwin G. Van Meir, Hongzheng Zhang, Wil Eijckenboom, Ad Gillis, Esther Korpershoek, Leendert Looijenga, Wolter Oosterhuis, Hans Stoop, Kim E. van Kessel, Ellen C. Zwarthoff, Chiara Calatozzolo, Lucia Cuppini, Stefania Cuzzubbo, Francesco DiMeco, Gaetano Finocchiaro, Luca Mattei, Alessandro Perin, Bianca Pollo, Chu Chen, John Houck, Pawadee Lohavanichbutr, Arndt Hartmann, Christine Stoehr, Robert Stoehr, Helge Taubert, Sven Wach, Bernd Wullich, Witold Kycler, Dawid Murawa, Maciej Wiznerowicz, Ki Chung, W. Jeffrey Edenfield, Julie Martin, Eric Baudin, Glenn Bubley, Raphael Bueno, Assunta De Rienzo, William G. Richards, Steven Kalkanis, Tom Mikkelsen, Houtan Noushmehr, Lisa Scarpace, Nicolas Girard, Marta Aymerich, Elias Campo, Eva Giné, Armando López Guillermo, Nguyen Van Bang, Phan Thi Hanh, Bui Duc Phu, Yufang Tang, Howard Colman, Kimberley Evason, Peter R. Dottino, John A. Martignetti, Hani Gabra, Hartmut Juhl, Teniola Akeredolu, Serghei Stepa, Dave Hoon, Keunsoo Ahn, Koo Jeong Kang, Felix Beuschlein, Anne Breggia, Michael Birrer, Debra Bell, Mitesh Borad, Alan H. Bryce, Erik Castle, Vishal Chandan, John Cheville, John A. Copland, Michael Farnell, Thomas Flotte, Nasra Giama, Thai Ho, Michael Kendrick, Jean-Pierre Kocher, Karla Kopp, Catherine Moser, David Nagorney, Daniel O’Brien, Brian Patrick O’Neill, Tushar Patel, Gloria Petersen, Florencia Que, Michael Rivera, Lewis Roberts, Robert Smallridge, Thomas Smyrk, Melissa Stanton, R. Houston Thompson, Michael Torbenson, Ju Dong Yang, Lizhi Zhang, Fadi Brimo, Jaffer A. Ajani, Ana Maria Angulo Gonzalez, Carmen Behrens, Jolanta Bondaruk, Russell Broaddus, Bogdan Czerniak, Bita Esmaeli, Junya Fujimoto, Jeffrey Gershenwald, Charles Guo, Alexander J. Lazar, Christopher Logothetis, Funda Meric-Bernstam, Cesar Moran, Lois Ramondetta, David Rice, Anil Sood, Pheroze Tamboli, Timothy Thompson, Patricia Troncoso, Anne Tsao, Ignacio Wistuba, Candace Carter, Lauren Haydu, Peter Hersey, Valerie Jakrot, Hojabr Kakavand, Richard Kefford, Kenneth Lee, Georgina Long, Graham Mann, Michael Quinn, Robyn Saw, Richard Scolyer, Kerwin Shannon, Andrew Spillane, Jonathan Stretch, Maria Synott, John Thompson, James Wilmott, Hikmat Al-Ahmadie, Timothy A. Chan, Ronald Ghossein, Anuradha Gopalan, Douglas A. Levine, Victor Reuter, Samuel Singer, Bhuvanesh Singh, Nguyen Viet Tien, Thomas Broudy, Cyrus Mirsaidi, Praveen Nair, Paul Drwiega, Judy Miller, Jennifer Smith, Howard Zaren, Joong-Won Park, Nguyen Phi Hung, Electron Kebebew, W. Marston Linehan, Adam R. Metwalli, Karel Pacak, Peter A. Pinto, Mark Schiffman, Laura S. Schmidt, Cathy D. Vocke, Nicolas Wentzensen, Robert Worrell, Hannah Yang, Marc Moncrieff, Chandra Goparaju, Jonathan Melamed, Harvey Pass, Natalia Botnariuc, Irina Caraman, Mircea Cernat, Inga Chemencedji, Adrian Clipca, Serghei Doruc, Ghenadie Gorincioi, Sergiu Mura, Maria Pirtac, Irina Stancul, Diana Tcaciuc, Monique Albert, Iakovina Alexopoulou, Angel Arnaout, John Bartlett, Jay Engel, Sebastien Gilbert, Jeremy Parfitt, Harman Sekhon, George Thomas, Doris M. Rassl, Robert C. Rintoul, Carlo Bifulco, Raina Tamakawa, Walter Urba, Nicholas Hayward, Henri Timmers, Anna Antenucci, Francesco Facciolo, Gianluca Grazi, Mirella Marino, Roberta Merola, Ronald de Krijger, Anne-Paule Gimenez-Roqueplo, Alain Piché, Simone Chevalier, Ginette McKercher, Kivanc Birsoy, Gene Barnett, Cathy Brewer, Carol Farver, Theresa Naska, Nathan A. Pennell, Daniel Raymond, Cathy Schilero, Kathy Smolenski, Felicia Williams, Carl Morrison, Jeffrey A. Borgia, Michael J. Liptay, Mark Pool, Christopher W. Seder, Kerstin Junker, Larsson Omberg, Mikhail Dinkin, George Manikhas, Domenico Alvaro, Maria Consiglia Bragazzi, Vincenzo Cardinale, Guido Carpino, Eugenio Gaudio, David Chesla, Sandra Cottingham, Michael Dubina, Fedor Moiseenko, Renumathy Dhanasekaran, Karl-Friedrich Becker, Klaus-Peter Janssen, Julia Slotta-Huspenina, Mohamed H. Abdel-Rahman, Dina Aziz, Sue Bell, Colleen M. Cebulla, Amy Davis, Rebecca Duell, J. Bradley Elder, Joe Hilty, Bahavna Kumar, James Lang, Norman L. Lehman, Randy Mandt, Phuong Nguyen, Robert Pilarski, Karan Rai, Lynn Schoenfield, Kelly Senecal, Paul Wakely, Paul Hansen, Ronald Lechan, James Powers, Arthur Tischler, William E. Grizzle, Katherine C. Sexton, Alison Kastl, Joel Henderson, Sima Porten, Jens Waldmann, Martin Fassnacht, Sylvia L. Asa, Dirk Schadendorf, Marta Couce, Markus Graefen, Hartwig Huland, Guido Sauter, Thorsten Schlomm, Ronald Simon, Pierre Tennstedt, Oluwole Olabode, Mark Nelson, Oliver Bathe, Peter R. Carroll, June M. Chan, Philip Disaia, Pat Glenn, Robin K. Kelley, Charles N. Landen, Joanna Phillips, Michael Prados, Jeffry Simko, Karen Smith-McCune, Scott VandenBerg, Kevin Roggin, Ashley Fehrenbach, Ady Kendler, Suzanne Sifri, Ruth Steele, Antonio Jimeno, Francis Carey, Ian Forgie, Massimo Mannelli, Michael Carney, Brenda Hernandez, Benito Campos, Christel Herold-Mende, Christin Jungk, Andreas Unterberg, Andreas von Deimling, Aaron Bossler, Joseph Galbraith, Laura Jacobus, Michael Knudson, Tina Knutson, Deqin Ma, Mohammed Milhem, Rita Sigmund, Andrew K. Godwin, Rashna Madan, Howard G. Rosenthal, Clement Adebamowo, Sally N. Adebamowo, Alex Boussioutas, David Beer, Thomas Giordano, Anne-Marie Mes-Masson, Fred Saad, Therese Bocklage, Lisa Landrum, Robert Mannel, Kathleen Moore, Katherine Moxley, Russel Postier, Joan Walker, Rosemary Zuna, Michael Feldman, Federico Valdivieso, Rajiv Dhir, James Luketich, Edna M. Mora Pinero, Mario Quintero-Aguilo, Carlos Gilberto Carlotti, Jose Sebastião Dos Santos, Rafael Kemp, Ajith Sankarankuty, Daniela Tirapelli, James Catto, Kathy Agnew, Elizabeth Swisher, Jenette Creaney, Bruce Robinson, Carl Simon Shelley, Eryn M. Godwin, Sara Kendall, Cassaundra Shipman, Carol Bradford, Thomas Carey, Andrea Haddad, Jeffey Moyer, Lisa Peterson, Mark Prince, Laura Rozek, Gregory Wolf, Rayleen Bowman, Kwun M. Fong, Ian Yang, Robert Korst, W. Kimryn Rathmell, J. Leigh Fantacone-Campbell, Jeffrey A. Hooke, Albert J. Kovatich, Craig D. Shriver, John DiPersio, Bettina Drake, Ramaswamy Govindan, Sharon Heath, Timothy Ley, Brian Van Tine, Peter Westervelt, Mark A. Rubin, Jung Il Lee, Natália D. Aredes, Armaz Mariamidze. A Comprehensive Pan-Cancer Molecular Study of Gynecologic and Breast Cancers. Cancer Cell, 2018. [PubMed]
52. Jiao Yuan, Zhongyi Hu, Brandon A. Mahal, Sihai D. Zhao, Kevin H. Kensler, Jingjiang Pi, Xiaowen Hu, Youyou Zhang, Yueying Wang, Junjie Jiang, Chunsheng Li, Xiaomin Zhong, Kathleen T. Montone, Guoqiang Guan, Janos L. Tanyi, Yi Fan, Xiaowei Xu, Mark A. Morgan, Meixiao Long, Yuzhen Zhang, Rugang Zhang, Anil K. Sood, Timothy R. Rebbeck, Chi V. Dang, Lin Zhang. Integrated Analysis of Genetic Ancestry and Genomic Alterations across Cancers. Cancer Cell, 2018. [PubMed]
53. NS Abul-Husn, EE Kenny. Personalized medicine and the power of electronic health records. Cell., 2019. [PubMed]
54. SA Tishkoff, FA Reed, FR Friedlaender, C Ehret, A Ranciaro, A Froment. The genetic structure and history of Africans and African Americans. Science., 2009. [PubMed]
55. JN Weinstein, EA Collisson, GB Mills, S KRM, BA Ozenberger. The Cancer Genome Atlas Pan-Cancer analysis project. Nat Genet, 2013. [PubMed]
56. L Ding, MH Bailey, E Porta-Pardo, V Thorsson, A Colaprico, D Bertrand. Perspective on oncogenic processes at the end of the beginning of cancer genomics. Cell, 2018. [PubMed]
57. S Park, F Supek, B Lehner. Systematic discovery of germline cancer predisposition genes through the identification of somatic second hits. Nat Commun, 2018. [PubMed]
58. H Carter, R Marty, M Hofree, AM Gross, J Jensen, KM Fisch. Interaction landscape of inherited polymorphisms with somatic events in cancer. Cancer Discov, 2017. [PubMed]
59. S Shahamatdar, MX He, MA Reyna, A Gusev, SH AlDubayan, EM Van Allen. Germline features associated with immune infiltration in solid tumors. Cell Rep, 2020. [PubMed]
60. Michael F. Walsh, Deborah I. Ritter, Chimene Kesserwan, Dmitriy Sonkin, Debyani Chakravarty, Elizabeth Chao, Rajarshi Ghosh, Yelena Kemel, Gang Wu, Kristy Lee, Shashikant Kulkarni, Dale Hedges, Diana Mandelker, Ozge Ceyhan‐Birsoy, Minjie Luo, Michael Drazer, Liying Zhang, Kenneth Offit, Sharon E. Plon. Integrating somatic variant data and biomarkers for germline variant classification in cancer predisposition genes. Human Mutation, 2018. [PubMed]
61. JR Ramroop, MM Gerber, AE Toland. Germline variants impact somatic events during tumorigenesis. Trends Genet, 2019. [PubMed]
62. 62.Campbell PJ, Getz G, Korbel JO et al. Pan-cancer analysis of whole genomes. Nature. 2020;578:82–93. 10.1038/s41586-020-1969-6.
63. 63.Waszak SM, Tiao G, Zhu B, Rausch T, Muyas F, Rodríguez-Martín B, et al. Germline determinants of the somatic mutation landscape in 2,642 cancer genomes. bioRxiv. 2017;208330.
64. JR Lupski, JW Belmont, E Boerwinkle, RA Gibbs. Clan genomics and the complex architecture of human disease. Cell., 2011. [PubMed]
65. LA Hindorff, VL Bonham, LC Brody, MEC Ginoza, CM Hutter, TA Manolio. Prioritizing diversity in human genomics research. Nat Rev Genet, 2018. [PubMed]